|
Nxera Pharma Co., Ltd. is a technology-driven biopharmaceutical company engaged in the research, development, and commercialization of specialty medicines. The company operates a single pharmaceutical business segment, focusing on addressing unmet medical needs in Japan, South Korea, and the broader Asia-Pacific region. Its core activities span the entire drug development lifecycle, from early-stage discovery and translational medicine to clinical trials and sales. Key subsidiaries include Nxera Pharma UK Limited, which handles GPCR structural analysis and lead compound generation using the proprietary NxStaR technology, and Nexera Pharma Japan Co., Ltd., which manages clinical development and sales in Japan. Nxera Pharma Korea Co., Ltd. oversees operations in South Korea. The company utilizes the NxWave platform for rational structure-based drug design targeting GPCRs. Established in 1990 as Sosei Co. Ltd., the group has evolved to include nine consolidated subsidiaries, with a strategic focus on in-house development, in-licensed assets, and partnerships for global commercialization while retaining rights for the Asia-Pacific market. Summarised from the annual report, fiscal year ended Dec 2025 |
Industry Biotechnology | Homepage nxera.life |
| Sector Healthcare | IR page investors.nxera.life | |
|
Tags
specialty pharmaceuticals, gpcr, structure-based drug design, translational medicine, clinical development, biopharmaceutical r&d, Nxera Pharma UK Limited, Nexera Pharma Japan Co. Ltd., Nxera Pharma Korea Co. Ltd., NxStaR, NxWave, Heptares Therapeutics Zurich AG, Sosei Co. Ltd.
|
Press page investors.nxera.life/news |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 111.046B |
| Market cap (USD) | $ 694.044M |
| P/E | -20.02 |
| PEG | — |
| P/BV | 1.73 |
| P/S | 3.13 |
| P/OCF | -41.62 |
| P/FCF | -33.72 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -19.3% |
| ROI | -15.3% |
| ROIC | -7.7% |
| Profit margin | -42.3% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -64.7% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.615B | 28.835B | 12.766B | 15.569B | 17.712B | 8.842B | 9.726B | 2.872B | 18.901B | 18.901B | 8.151B | 2.069B | 1.958B |
| Net profit | -12.53B | -4.838B | -7.193B | 382M | 1.017B | 1.479B | 1.432B | -5.977B | 9.311B | 9.311B | -1.432B | -122M | -646M |
| Free cash flow | -3.293B | -9.255B | -6.124B | 9.649B | 6.894B | 4.567B | 3.161B | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Mar 2017 | Mar 2018 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (JPY) | — | — | 987M | 1.92B | 939M | 2.14B | 2.46B | 5.06B | 6.7B | 7.73B |
| ↳ YoY growth | +94.9% | -51.2% | +127.7% | +15.2% | +105.7% | +32.2% | +15.5% | |||
| ↳ 5y CAGR | +38.7% | +28.3% | +52.4% | |||||||
| Borrowings, non-current (JPY) | — | — | — | — | — | — | — | 32.7B | 26.9B | 21.1B |
| Lease liabilities (JPY) | — | — | — | 1.88B | 1.83B | 1.83B | 1.75B | 4.82B | 4.38B | 4.39B |
| Cash and deposits (JPY) | 13.9B | 28.3B | 18.8B | 15.4B | 40B | 60.1B | 66.6B | 49.1B | 32.3B | 20.4B |
| Intangible assets (JPY) | — | — | 14.4B | 13B | 11.8B | 9.12B | 8.58B | 52.3B | 51.9B | 49.2B |
| Net debt (borrowings + leases - cash) (JPY) | — | — | — | — | — | — | — | -11.6B | -1B | 5.14B |
| Cash flow detail | ||||||||||
| Operating cash flow (JPY) | 12.9B | -2.17B | -4B | 3.44B | 4.67B | 7.1B | 9.95B | -5.27B | -7.72B | -2.67B |
| Purchases of property, plant and equipment (JPY) | — | — | -1.81B | -271M | -92M | -193M | -277M | -804M | -526M | -448M |
| Purchases of intangible assets (JPY) | — | — | -352M | -9M | -13M | -8M | -26M | -47M | -1.01B | -177M |
| Change in receivables (cash effect) (JPY) | — | — | -243M | -880M | 909M | -799M | -210M | 1.32B | -742M | -1.04B |
| Change in inventories (cash effect) (JPY) | — | — | — | — | — | — | -32M | 1.91B | -5.94B | -2.46B |
| Change in payables (cash effect) (JPY) | — | — | 210M | -258M | 61M | -184M | 315M | 1.55B | -487M | 2.97B |
| Interest paid (cash effect) (JPY) | — | — | -99M | -103M | -60M | -157M | -171M | -241M | -435M | -531M |
| Income taxes paid (cash effect) (JPY) | — | — | -23M | -93M | -168M | -296M | -262M | -1.39B | -428M | -241M |
| Share-based compensation (JPY) | — | — | 421M | 384M | 626M | 713M | 700M | 870M | 1.4B | 1.95B |
| Operating cash flow before change in receivables (JPY) | — | — | -3.75B | 4.32B | 3.76B | 7.89B | 10.2B | -6.59B | -6.98B | -1.63B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | — | — | -6.15B | 3.16B | 4.57B | 6.89B | 9.65B | -6.12B | -9.26B | -3.29B |
| Income detail | ||||||||||
| Research and development expense (JPY) | — | — | 5.38B | 4.29B | 3.79B | 5.93B | 7.45B | 10.1B | 11.8B | 14.5B |
| ↳ 5y CAGR | +13.4% | +22.5% | +30.7% | |||||||
| Total comprehensive income (JPY) | — | — | -7.62B | 2.37B | 661M | 5.62B | -255M | -1.12B | 319M | -9.47B |
| Comprehensive income to owners (JPY) | 5.28B | -1.23B | -7.62B | 2.37B | 661M | 5.62B | -255M | -1.12B | 319M | -9.47B |
| Reported | Jun 23, 2017 | Jun 22, 2018 | Mar 25, 2020 | Mar 24, 2021 | Mar 24, 2021 | Mar 24, 2022 | Mar 27, 2024 | Mar 27, 2024 | Mar 26, 2025 | Mar 25, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
Nxera Pharma Announces Vamorolone Selected for South Korea’s Accelerated Reimbursement Pilot Program for Rare Disease Treatments • Vamorolone is one of five treatments selected for the rare disease reimbursement pilot program. • The program aims to shorten the National Health Insurance listing process to within 100 days. • Together with GIFT priority review, the accelerated reimbursement pathway could enable a South Korean launch in 2027, earlier than the previously announced target of 2028. Tokyo, Japan and Cambridge, UK, 6 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that vamorolone, a treatment for Duchenne muscular dystrophy (DMD), has been selected for the South Korean government’s Accelerated Reimbursement Pilot Program for Rare Disease Treatments. Vamorolone is one of five treatments selected for the pilot program. The program aims to improve access to rare disease treatments by streamlining the National Health Insurance (NHI) listing process following regulatory approval, with a target duration of no more than 100 days. It combines simplified pre-listing assessment and pricing procedures with post-listing reassessment based on real-world evidence (RWE), supporting earlier patient access alongside continued evaluation of therapeutic value. On 22 October 2026, Nxera announced the submission of a Marketing Authorization Application (MAA) for vamorolone to South Korea’s Ministry of Food and Drug Safety (MFDS). Vamorolone has already received Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation in South Korea and is currently under regulatory review. Taking into account priority review under GIFT, Nxera is targeting regulatory approval in the third quarter of 2027. The accelerated reimbursement pathway, together with GIFT priority review, could enable Nxera to bring forward the commercial launch of vamorolone in South Korea to 2027 from the previously announced target of 2028. The Company will work closely with the relevant South Korean authorities to advance regulatory approval, reimbursement and product supply preparations, with the aim of launching vamorolone concurrently with its NHI listing. The timing of launch will depend on the progress of regulatory review and reimbursement procedures. Following NHI listing and commercial launch, real-world data (RWD) from Korean patients is expected to be collected through a patient registry established by the Health Insurance Review & Assessment Service (HIRA). The resulting RWE is expected to support reassessment of vamorolone’s longterm clinical outcomes and therapeutic value.
Mr. MinBok Lee, President and Representative Director of Nxera Pharma Korea, commented: " Selection for this pilot program is an important step towards giving patients with DMD and their families in South Korea earlier access to a new treatment option. Together with the GIFT priority review pathway, it could help us shorten the time from regulatory review to reimbursed availability of vamorolone. We are grateful to Santhera Pharmaceuticals for the scientific evidence and close collaboration that have supported this progress. We will continue to work with the Korean authorities and our partners to secure regulatory approval, complete reimbursement procedures and establish a reliable supply of vamorolone for patients.” About South Korea’s Accelerated Reimbursement Pilot Program for Rare Disease Treatments Introduced by the South Korean government in 2026, the pilot program is designed to improve timely access to medicines for patients with serious rare diseases and to evaluate the feasibility and effectiveness of a new accelerated reimbursement system. Predefined contractual terms replace separate negotiations on drug prices and total pharmaceutical expenditure under the conventional listing process. Prices are set with reference to 90% of the lowest adjusted price across eight reference countries (A8). Reimbursement prices and coverage conditions may subsequently be revised following reassessment of real-world clinical outcomes. The A8 reference countries are the United States, United Kingdom, Germany, France, Italy, Switzerland, Japan and Canada. About Duchenne Muscular Dystrophy Duchenne muscular dystrophy (DMD) is a rare inherited X-chromosome-linked disease, which almost exclusively affects males. DMD is characterized by inflammation which is present at birth or shortly thereafter. Inflammation leads to fibrosis of muscle and is clinically manifested by progressive muscle degeneration and weakness. Major milestones in the disease are the loss of ambulation, the loss of selffeeding, the start of assisted ventilation, and the development of cardiomyopathy. DMD typically reduces life expectancy to before the fourth decade due to respiratory and/or cardiac failure. About vamorolone Vamorolone is a dissociative corticosteroid approved for the treatment of Duchenne muscular dystrophy (DMD). It binds selectively to the glucocorticoid receptor and triggers anti-inflammatory activity through inhibition of NF‑κB-mediated gene transcription, while inducing reduced transactivation of other genes [1]. Vamorolone is not a substrate for 11‑β-hydroxysteroid dehydrogenase (11β-HSD) enzymes, which are involved in the local amplification of glucocorticoid activity in tissues and have been implicated in corticosteroid-associated toxicity [2,3]. This pharmacological profile is the basis for its classification as a dissociative corticosteroid, designed to preserve anti-inflammatory efficacy while reducing the systemic effects associated with long-term conventional corticosteroid therapy [1–3]. In the pivotal Phase 2b VISION-DMD study, vamorolone met its primary endpoint, demonstrating a statistically significant improvement in Time to Stand (TTSTAND) velocity versus placebo at 24 weeks (p = 0.002) [4]. The most commonly reported adverse reactions were cushingoid features, vomiting, weight increase, increased appetite, and irritability; most were mild to moderate in severity [1]. Long-term data from up to eight years of vamorolone treatment were presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in March 2026[5,6]. In propensity-matched analyses, vamorolone demonstrated durable efficacy comparable to standard-of-care corticosteroids and a differentiated safety profile: a lower incidence of vertebral fractures versus deflazacort-treated cohorts (8.1% vs 41.9%; p = 0.0082) [5]; maintained normal growth trajectory with a mean height advantage of 12.17 cm versus conventional corticosteroids (p < 0.0001) [5,6], and a lower incidence of cataracts versus deflazacort (p = 0.015), with no observed cases of glaucoma [5]. 2 of 3
References
[1] AGAMREE® (vamorolone) Summary of Product Characteristics. European Medicines Agency; authorised 14 December 2023. [2] Heier CR, Damsker JM, Yu Q, et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. Life Sci Alliance. 2019;2(1): e201800186. [3] Reeves EKM, Hoffman EP, Nagaraju K, et al. VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem. 2013; 21(8): 2241–2249. [4] Dang UJ, Damsker JM, Guglieri M, et al. Efficacy and safety of vamorolone over 48 weeks in boys with Duchenne muscular dystrophy (VISIONDMD). Neurology. 2024;102(5): e208112. [5] Guglieri M, et al. Long-term impact of vamorolone on bone health compared to standard of care glucocorticoids in boys with Duchenne muscular dystrophy. Poster 62S, MDA Clinical & Scientific Conference 2026. [6] McDonald CM, et al. Comparative analysis of long-term effectiveness of vamorolone versus standard of care glucocorticoid treatment in boys with Duchenne muscular dystrophy. Poster 23S, MDA Clinical & Scientific Conference 2026.
–END– About Nxera Pharma Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, newgeneration commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies powered by its unique NxWave™ GPCR structure-based drug discovery platform. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Nxera Pharma Co., Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.